SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Cannabis >

Zynerba Pharmaceuticals (ZYNE)

ZYNE RSS Feed
Add ZYNE Price Alert      Hide Sticky   Hide Intro
Moderator: Cbdpotential, djmurdock
Search This Board: 
Last Post: 4/16/2017 5:10:30 PM - Followers: 47 - Board type: Free - Posts Today: 0


Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Investor Relations

Corporate Profile

Zynerba (NASDAQ: ZYNE) is pioneering the development of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In June 2016, the company initiated the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in August 2016, initiated the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. A Phase 2 clinical trial in patients with Fragile X syndrome will be initiated in the second half of 2016. 

ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in preclinical development. A Phase 1 clinical trial is planned in the first half of 2017.

In August 2015, Zynerba completed an initial public offering, raising net proceeds of $42.1 million. As of June 30, 2016, cash and cash equivalents totaled $32.1 million, which is projected to fund five Phase 2 clinical trials through 2017.





Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "ZYNE" on August 5, 2015.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering is being made only by means of a prospectus.



Extremely low float:

Fundamentals

A table providing the fundamentals of the stock
EPS (TTM) 9/30/2016 | -2.47
P/E Ratio 9/30/2016 | --
Market Cap Micro Cap | 146M
Shares Outstanding 9.95M
Float 7.2M

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ZYNE
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ZYNE News: Statement of Changes in Beneficial Ownership (4) 04/04/2017 04:14:28 PM
ZYNE News: Statement of Changes in Beneficial Ownership (4) 04/04/2017 04:14:02 PM
ZYNE News: Statement of Changes in Beneficial Ownership (4) 04/04/2017 04:13:37 PM
ZYNE News: Statement of Changes in Beneficial Ownership (4) 04/04/2017 04:13:11 PM
ZYNE News: Pain-Reducing Combination Therapies Proving Successful thanks to Innovative, Specialty Pharma Players 03/30/2017 08:30:00 AM
PostSubject
#326  Sticky Note Slideshow for new investors djmurdock 12/17/16 05:09:50 PM
#563   Easily WolfOfGrnStreet 04/16/17 05:10:30 PM
#562   I think we see $40 at least when djmurdock 04/16/17 04:12:47 PM
#561   $75-$100 by the EOY IMO SYNTHETIC WINS in WolfOfGrnStreet 04/16/17 12:48:11 AM
#560   Sky is the limit with ZYNE. Adding more. WolfOfGrnStreet 04/12/17 03:05:46 PM
#559   ZYNE is Smokin! The Strongest Biotech Sector Stock bratby 04/12/17 05:47:37 AM
#558   Yes sir! WolfOfGrnStreet 04/11/17 08:33:28 PM
#557   Won't be long... I keep adding. This a surfer 04/11/17 04:09:25 PM
#556   GWPH Who? WolfOfGrnStreet 04/10/17 07:52:15 PM
#555   Looks like someone in on the know is djmurdock 04/10/17 05:26:11 PM
#554   ZYNE is on ETF, and OWCP will be Up 4 Air 04/10/17 05:19:57 PM
#553   ZYNE is listed on the newly released Horizon's Up 4 Air 04/10/17 05:17:58 PM
#552   Charts show move to $44 before any big resistence. biotechnician 04/10/17 03:36:32 PM
#551   12% something is up! a surfer 04/10/17 02:43:06 PM
#550   Holy crap! Nice day...haven't seen any news BigD_McGee 04/10/17 01:25:49 PM
#549   Nice move today $zyne Cbdpotential 04/07/17 07:01:34 PM
#548   Amen! a surfer 04/07/17 03:51:01 PM
#547   We're looking good here! Could be explosive in July/August djmurdock 04/07/17 01:38:08 PM
#546   $ZYNE$ Stairway to heaven surfgreen 04/07/17 11:14:00 AM
#545   It took a breather around $20 for a CoachMarc 04/06/17 02:27:47 PM
#544   Looking good today $zyne Cbdpotential 04/06/17 11:25:50 AM
#543   Great potential here Imo $ZYNE Cbdpotential 04/05/17 10:37:23 AM
#542   Over 5%!! I'd say that's awesome! a surfer 04/05/17 10:36:42 AM
#541   $ZYNE Holding up well 20$ Cbdpotential 04/05/17 10:32:43 AM
#540   I agree... It might stay in this tight djmurdock 04/01/17 08:32:43 PM
#539   Looks like it is finding very strong support CoachMarc 03/30/17 02:56:17 PM
#538   stellar day!!! djmurdock 03/27/17 08:04:48 PM
#537   Beautiful!! :) a surfer 03/27/17 05:46:47 PM
#536   Bazinga madmanmartinwins 03/27/17 03:41:29 PM
#535   Love $ZYNE It! Cbdpotential 03/27/17 01:11:06 PM
#534   2017 Financial Outlook a surfer 03/27/17 07:32:46 AM
#533   Closed one cent above pervious high 4 days a surfer 03/23/17 04:12:29 PM
#532   IPO today? a surfer 03/23/17 04:11:01 PM
#531   ZYNE market cap 260 million. Similar company TRPX excboe 03/23/17 12:11:48 PM
#530   Beautiful day! a surfer 03/23/17 11:29:29 AM
#529   Bout time ZYNE -This chart is amazingly predictable. surfgreen 03/23/17 11:04:06 AM
#528   :-) $ZYNE Cbdpotential 03/22/17 10:54:35 PM
#527   Zynerba's transdermal approach has significant benefits djmurdock 03/22/17 09:54:01 PM
#526   Awesome new presentation!!! djmurdock 03/22/17 09:48:08 PM
#525   More WolfOfGrnStreet 03/21/17 12:33:01 AM
#524   22$+ Cbdpotential 03/20/17 10:19:29 AM
#523   Biotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth Source Cbdpotential 03/15/17 09:29:32 AM
#522   Great news !!! djmurdock 03/14/17 02:10:45 AM
#521   http://ir.zynerba.com/phoenix.zhtml?c=253915&p=irol-newsArticle&ID=2253370 djmurdock 03/14/17 02:09:49 AM
#520   Strong close! Wish my other stocks we're doing djmurdock 03/08/17 04:20:50 PM
#519   Out of the weekly cloud Catalysts coming Support holding Quokkie 03/02/17 06:55:06 PM
#518   Looks like we are hitting stubborn resistance at Gpheart2016 03/02/17 12:03:24 PM
#517   Record shorts Anticipated positive earnings Hold on tight. Quokkie 03/01/17 09:30:38 AM
#516   Report seems conservative in $30s. biotechnician 02/28/17 02:37:44 PM
#515   Monster stock! $ZYNE Cbdpotential 02/27/17 04:37:41 PM
#514   http://www.thenewstribune.com/latest-news/article134608869.html Medical mj safe Quokkie 02/25/17 02:22:09 AM
PostSubject